Stocks News

LAST PRICE
42.1000
TODAY'S CHANGE (%)
Trending Down-0.1400 (-0.3314%)

Bid / Lots
41.1900/ 1
Ask / Lots
42.9600/ 1
Open / Previous Close
42.0600 / 42.2400
Day Range
Low 41.8900
High 42.3900
52 Week Range
Low 37.2165
High 47.4400
Volume
925,569
above average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Oct 29, 2024
- QIAGEN Says QIAstat-Dx Respiratory Test Receives FDA Clearance, from 5:19AM ET on Tuesday Oct 29, 2024 by MT Newswires
  5:19AM ET on Tuesday Oct 29, 2024 by MT Newswires
  Companies Mentioned: QGEN
  05:19 AM EDT, 10/29/2024 (MT Newswires) -- QIAGEN (QGEN) said Tuesday the US Food and Drug Administration has approved its QIAstat-Dx respiratory panel mini test for clinical use. The company said the test is designed to help diagnose upper respirat...
- QIAGEN receives FDA clearance for QIAstat-Dx mini panel to improve precision in outpatient respiratory treatment, from 2:30AM ET on Tuesday Oct 29, 2024 by Dow Jones
  2:30AM ET on Tuesday Oct 29, 2024 by Dow Jones
  Companies Mentioned: QGEN
  
  QIAGEN receives FDA clearance for QIAstat-Dx mini panel to improve precision in outpatient respiratory treatment
  
  QIAstat-Dx Respiratory Panel Mini targets the five most actionable respiratory pathogens in outpatient settings to help clinicians make precise treatment decisions // With the new test and the 21-target QIAstat-Dx Respiratory Panel Plus, clinicians can fine-tune their diagnostic approach for individual patients, promoting better diagnostic stewardship // FDA decision marks third positive U.S. regulatory outcome for QIAstat-Dx to date in 2024
Oct 17, 2024
- HSBC Downgrades QIAGEN to Hold From Buy, Price Target is $49, from 6:44AM ET on Thursday Oct 17, 2024 by MT Newswires
  6:44AM ET on Thursday Oct 17, 2024 by MT Newswires
  Companies Mentioned: QGEN
  06:44 AM EDT, 10/17/2024 (MT Newswires) -- QIAGEN (QGEN) has an average outperform rating and a price target range of $43.81 to $60, according to analysts polled by Capital IQ. (MT Newswires covers equity, commodity and economic research from major ...
- DJ Qiagen Cut to Hold From Buy by HSBC, from 6:33AM ET on Thursday Oct 17, 2024 by Dow Jones
  6:33AM ET on Thursday Oct 17, 2024 by Dow Jones
  Companies Mentioned: QGEN
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/QGEN/analyst-ratings
  
  (END) Dow Jones Newswires
  
  October 17, 2024 06:33 ET (10:33 GMT)
Oct 10, 2024
- QIAGEN expands automated liquid biopsy portfolio to enhance oncology, prenatal care and organ transplant applications, from 4:05PM ET on Thursday Oct 10, 2024 by Dow Jones
  4:05PM ET on Thursday Oct 10, 2024 by Dow Jones
  Companies Mentioned: QGEN
  
  QIAGEN expands automated liquid biopsy portfolio to enhance oncology, prenatal care and organ transplant applications
  
  Portfolio expansion reinforces QIAGEN's leadership in automated solutions for non-invasive liquid biopsy applications combined with complete workflows // New ccfDNA Kit upgrade with urine protocol for use on EZ1 and 2 instruments designed to enhance liquid biopsy workflows for cancer research // New QIAsymphony DSP Circulating DNA and Maxi Kits deliver high-quality cfDNA for use in downstream applications

Today
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Medpace Holdings, Inc. - MEDP, from 4 hours ago by Dow Jones
  4 hours ago by Dow Jones
  Companies Mentioned: MEDP
- MEDP Investigation Notice: Kessler Topaz Meltzer & Check, LLP Encourages Medpace Holdings, Inc. (MEDP) Investors with Significant Losses to Contact the Firm, from 6 hours ago by Newsfile
  6 hours ago by Newsfile
  Companies Mentioned: MEDP
- MEDP Investigation Notice: Kessler Topaz Meltzer & Check, LLP Encourages Medpace Holdings, Inc. (MEDP) Investors with Significant Losses to Contact the Firm, from 6 hours ago by Dow Jones
  6 hours ago by Dow Jones
  Companies Mentioned: MEDP
- Medpace Holdings, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Encouraged To Contact The Schall Law Firm, from 9 hours ago by Dow Jones
  9 hours ago by Dow Jones
  Companies Mentioned: MEDP
- Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Medpace Holdings, Inc. (MEDP) And Encourages Stockholders to Reach Out, from 11 hours ago by Dow Jones
  11 hours ago by Dow Jones
  Companies Mentioned: MEDP
Yesterday
- DJ Exelixis Is Maintained at Buy by Guggenheim, from 3:36PM ET on Wednesday Oct 30, 2024 by Dow Jones
  3:36PM ET on Wednesday Oct 30, 2024 by Dow Jones
  Companies Mentioned: EXEL
- DJ BioMarin Pharmaceutical Is Maintained at Neutral by Citigroup, from 2:44PM ET on Wednesday Oct 30, 2024 by Dow Jones
  2:44PM ET on Wednesday Oct 30, 2024 by Dow Jones
  Companies Mentioned: BMRN
- DJ Exelixis Is Maintained at Equal-Weight by Stephens & Co., from 2:40PM ET on Wednesday Oct 30, 2024 by Dow Jones
  2:40PM ET on Wednesday Oct 30, 2024 by Dow Jones
  Companies Mentioned: EXEL
- Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Medpace Holdings, Inc. for potential violations of securities laws, from 2:30PM ET on Wednesday Oct 30, 2024 by Dow Jones
  2:30PM ET on Wednesday Oct 30, 2024 by Dow Jones
  Companies Mentioned: MEDP
- DJ BioMarin Pharmaceutical Is Maintained at Hold by Canaccord Genuity, from 1:36PM ET on Wednesday Oct 30, 2024 by Dow Jones
  1:36PM ET on Wednesday Oct 30, 2024 by Dow Jones
  Companies Mentioned: BMRN

Qiagen NV
NYSE:QGENUnited States

Search Criteria

Oct 29, 2024

QIAGEN Says QIAstat-Dx Respiratory Test Receives FDA Clearance, from 5:19AM ET on Tuesday Oct 29, 2024 by MT Newswires

QIAGEN receives FDA clearance for QIAstat-Dx mini panel to improve precision in outpatient respiratory treatment, from 2:30AM ET on Tuesday Oct 29, 2024 by Dow Jones

Oct 17, 2024

HSBC Downgrades QIAGEN to Hold From Buy, Price Target is $49, from 6:44AM ET on Thursday Oct 17, 2024 by MT Newswires

DJ Qiagen Cut to Hold From Buy by HSBC, from 6:33AM ET on Thursday Oct 17, 2024 by Dow Jones

Oct 10, 2024

QIAGEN expands automated liquid biopsy portfolio to enhance oncology, prenatal care and organ transplant applications, from 4:05PM ET on Thursday Oct 10, 2024 by Dow Jones

Peers Headlines

Today

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Medpace Holdings, Inc. - MEDP, from 4 hours ago by Dow Jones

MEDP Investigation Notice: Kessler Topaz Meltzer & Check, LLP Encourages Medpace Holdings, Inc. (MEDP) Investors with Significant Losses to Contact the Firm, from 6 hours ago by Newsfile

MEDP Investigation Notice: Kessler Topaz Meltzer & Check, LLP Encourages Medpace Holdings, Inc. (MEDP) Investors with Significant Losses to Contact the Firm, from 6 hours ago by Dow Jones

Medpace Holdings, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Encouraged To Contact The Schall Law Firm, from 9 hours ago by Dow Jones

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Medpace Holdings, Inc. (MEDP) And Encourages Stockholders to Reach Out, from 11 hours ago by Dow Jones

Yesterday

DJ Exelixis Is Maintained at Buy by Guggenheim, from 3:36PM ET on Wednesday Oct 30, 2024 by Dow Jones

DJ BioMarin Pharmaceutical Is Maintained at Neutral by Citigroup, from 2:44PM ET on Wednesday Oct 30, 2024 by Dow Jones

DJ Exelixis Is Maintained at Equal-Weight by Stephens & Co., from 2:40PM ET on Wednesday Oct 30, 2024 by Dow Jones

Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Medpace Holdings, Inc. for potential violations of securities laws, from 2:30PM ET on Wednesday Oct 30, 2024 by Dow Jones

DJ BioMarin Pharmaceutical Is Maintained at Hold by Canaccord Genuity, from 1:36PM ET on Wednesday Oct 30, 2024 by Dow Jones